Headquartered in San Diego, CA Fiscal year ends December NASDAQ: VKTX vikingtherapeutics.com
Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies for obesity and metabolic disease. It currently has no product revenue.
Its lead program, VK2735, is a long-acting dual agonist of the GLP-1 and GIP receptors, developed in both subcutaneous injectable and oral tablet formulations. Phase 3 status:
- Subcutaneous VK2735 is in the VANQUISH-1 (obesity) and VANQUISH-2 (obesity with type 2 diabetes) trials, with 78-week weekly dosing.
- Oral VK2735 entered the SUNRISE-1 and SUNRISE-2 trials in October 2026.
The company is also testing maintenance regimens for long-term weight management. These include every-other-week and monthly injections and daily oral doses.
Other pipeline programs are:
- VK3019, a dual amylin and calcitonin receptor agonist for obesity, in Phase 1.
- VK2809, an oral thyroid hormone receptor beta agonist for metabolic and liver disease.
- VK0214, for the rare genetic disorder X-linked adrenoleukodystrophy (X-ALD).
Viking funds its work through equity and debt financing. In September 2026 it raised about $575 million gross through stock and convertible note offerings. It is building commercial infrastructure ahead of a potential VK2735 launch. Updated
A September raise left $960 million in cash, which management says funds multiple Phase 3 readouts starting in 2027 plus early commercial buildout. That spending on the VANQUISH Phase 3 trials and the new oral SUNRISE program widened the quarterly loss, missing expectations.
Eli Lilly (NYSE:LLY | LLY Price Prediction) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the rest of the glucagon-like…
Viking Therapeutics (NASDAQ:VKTX | VKTX Price Prediction) reports third-quarter results on October 28, 2026. Shares fell 41.42% over the past month, so management has to make the case for its newly launched…
Rich Duprey Two biotech names are moving sharply lower Thursday morning while the sector benchmark grinds higher, a split move that puts the day’s action on the companies themselves rather than on any broader…
Two biotechnology names are lower in Wednesday morning trading for unrelated reasons, and the biotechnology sector itself isn’t selling off. Jaguar Health (NASDAQ:JAGX) stock is at $14.21, down 59%, while Viking Therapeutics…
Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether…
Eli Lilly just posted a quarter that crushed estimates on every major metric, yet the stock has spent the past month getting punished anyway. One of Wall Street's biggest banks thinks the…
Novo Nordisk (NYSE:NVO | NVO Price Prediction) laid out its long-term growth strategy at a capital markets day in London Monday morning, and the plan didn’t calm investor worries about the company’s…
Eli Lilly stakes its trillion-dollar valuation on mid-stage data for a two-drug obesity combo, and the September 30 readout will reveal whether eloraTZP is a genuine franchise leap or an expensive gamble…
FDA calendars are stacking up fast, obesity Phase 3 data is closing in, and three biotech names spanning the risk spectrum are quietly positioning for a pivotal back half of 2026.
The GLP-1 trade has matured from a single-stock story into a tiered opportunity set. Demand for obesity therapeutics keeps expanding as lower-cost, easier-to-administer oral pill versions of the current injectable GLP-1s are…
Big pharma’s appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a…
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX | VKTX Price Prediction) carries a 38.5% implied probability of being acquired before 2027,…
Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised…
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth. Five therapeutic categories are absorbing most strategic capital: radiopharmaceuticals, next-gen GLP-1,…
Amazon (NASDAQ: AMZN | AMZN Price Prediction) just made a quiet move that could reshape how Americans access weight-loss drugs. On April 9, 2026, it announced that its pharmacy unit will stock…
Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies for obesity and metabolic disease. It currently has no product revenue.
The Wall Street consensus 12-month price target for VKTX is $95.05. VKTX price prediction →
